
    
      Study duration:

        -  Screening period: up to 56 days

        -  Transition period between last sutimlimab dose and first dose of BIVV020 (for
           participants who were previously receiving sutimlimab): 14 days, included as part of the
           56-day Screening period Treatment duration: Minimum 52 weeks

      Visit frequency:

        -  Day 1

        -  Day 4

        -  Weeks 1 to 6: Weekly

        -  Weeks 7 to 12: Every other week

        -  Weeks 13 to 24: Every 4 weeks

        -  Weeks 25+: At least every 8 weeks

        -  End of Study visit: 22 weeks after the last dose of BIVV020
    
  